Circulating tumor cells in metastatic breast cancer: Monitoring response to chemotherapy and predicting progression-free survival

详细信息    查看全文

• 作者：Jian-ping Cheng (1)
  Ying Yan (1)
  Xiang-yi Wang (1)
  Yuan-li Lu (1)
  Yan-hua Yuan (1)
  Xiao-li Wang (1)
  Jun Jia (1)
  Jun Ren (1)
  
• 关键词：R737.9 ; Breast cancer ; Circulating tumor cells ; CK19 ; RT ; PCR ; ELISA
• 刊名：Chinese Journal of Cancer Research
• 出版年：2010
• 出版时间：September 2010
• 年：2010
• 卷：22
• 期：3
• 页码：201-210
• 全文大小：358KB
• 参考文献：1. Cristofanilli M, Hayes DF, Budd GT, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer[J]. J Clin Oncol 2005; 23:1420-430. CrossRef
  2. Bauernhofer T, Zenahlik S, Hofmann G, et al. Association of disease progression and poor overall survival with detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer[J]. Oncol Rep 2005; 13: 179-84.
  3. Hayes DF, Cristofanilli M, Budd GT, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival[J]. Clin Cancer Res 2006; 12:4218-224. CrossRef
  4. Kopfstein L, Christofori G. Metastasis: cell-autonomous mechanisms versus contributions by the tumor microenvironment[J]. Cell Mol Life Sci 2006; 63:449-68. 96-8">CrossRef
  5. Swenerton KD, Legha SS, Smith T, et al. Prognostic factors in metastatic breast cancer treated with combination chemotherapy[J]. Cancer Res 1979; 39:1552-562.
  6. Yagata H, Nakamura S, Toi M, et al. Evaluation of circulating tumor cells in patients with breast cancer: multi-institutional clinical trial in Japan[J]. Int J Clin Oncol 2008; 13:252-56. 9">CrossRef
  7. Cristofanilli M. Circulating tumor cells, disease progression, and survival in metastatic breast cancer[J]. Semin Oncol 2006; 33:S9–S14. CrossRef
  8. Andreopoulou E, Cristofanilli M. Circulating tumor cells as prognostic marker in metastatic breast cancer[J]. Expert Rev Anticancer Ther 2010; 10:171-77. 9.105">CrossRef
  9. Pierga JY, Bidard FC, Denis MG, et al. Prognostic value of peripheral blood double detection of CK19 and MUC1 mRNA positive cells detected by RT-quantitative PCR in 94 breast cancer patients with a follow up of 9 years[J]. Mol Oncol 2007; 1:267-68. 9.005">CrossRef
  10. You F, Roberts LA, Kang SP, et al. Low-level expression of HER2 and CK19 in normal peripheral blood mononuclear cells: relevance for detection of circulating tumor cells[J]. J Hematol Oncol 2008; 1:2. CrossRef
  11. Saloustros E, Mavroudis D. Cytokeratin 19-positive circulating tumor cells in early breast cancer prognosis[J]. Future Oncol 2010; 6:209-19. 9.147">CrossRef
  12. Paterlini-Brechot P, Benali NL. Circulating tumor cells (CTC) detection: clinical impact and future directions[J]. Cancer Lett 2007; 253:180-04. CrossRef
  13. Müller V, Stahmann N, Riethdorf S, et al. Circulating tumor cells in breast cancer: correlation to bone marrow micrometastases, heterogeneous response to systemic therapy and low proliferative activity[J]. Clin Cancer Res 2005; 11:3678-685. 9">CrossRef
  14. Budd GT, Cristofanilli M, Ellis MJ, et al. Circulating tumor cells versus imaging—predicting overall survival in metastatic breast cancer[J]. Clin Cancer Res 2006; 12:6403-409. 9">CrossRef
  15. Martin M, García-Sáenz JA, Maestro De las Casas ML, et al. Circulating tumor cells in metastatic breast cancer: timing of blood extraction for analysis[J]. Anticancer Res 2009; 29:4185-187.
  16. Bidard FC, Mathiot C, Degeorges A, et al. Clinical value of circulating endothelial cells and circulating tumor cells in metastatic breast cancer patients treated first line with bevacizumab and chemotherapy[J]. Ann Oncol 2010; Mar 16, [Epub ahead of print].
  17. De Giorgi U, Valero V, Rohren E, et al. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer[J]. J Clin Oncol 2009; 27:3303-311. 9.4423">CrossRef
  18. Cristofanilli M, Broglio KR, Guarneri V, et al. Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden[J]. Clin Breast Cancer 2007; 7:471-79. CrossRef
  19. Van’t Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer[J]. Nature 2002; 415: 530-36. CrossRef
  20. Reuben JM, Lee BN, Li C, et al. Circulating tumor cells and biomarkers: implications for personalized targeted treatments for metastatic breast cancer[J]. Breast J 2010; 16:327-30. 910.x">CrossRef
  21. Pierga JY, Bidard FC, Mathiot C, et al. Circulating tumor cell detection predicts early metastatic relapse after neoadjuvant chemotherapy in large operable and locally advanced breast cancer in a phase II randomized trial[J]. Clin Cancer Res 2008; 14:7004-010. CrossRef
  22. Pinzani P, Salvadori B, Simi L, et al. Isolation by size of epithelial tumor cells in peripheral blood of patients with breast cancer: correlation with real-time reverse transcriptase-polymerase chain reaction results and feasibility of molecular analysis by laser microdissection[J]. Hum Pathol 2006; 37:711-18. CrossRef
  23. Méhes G, Witt A, Kubista E, et al. Circulating breast cancer cells are frequently apoptotic[J]. Am J Pathol 2001; 159:17-0.
  24. Alix-Panabières C, Vendrell JP, Pellé O, et al. Detection and characterization of putative metastatic precursor cells in cancer patients[J]. Clin Chem 2007; 53:537-39. 9509">CrossRef
  25. Alix-Panabières C, Vendrell JP, Slijper M, et al. Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer[J]. Breast Cancer Res 2009; 11:R39. CrossRef
  26. Marrakchi R, Ouerhani S, Benammar S, et al. Detection of cytokeratin 19 mRNA and CYFRA 21-1 (cytokeratin 19 fragments) in blood of Tunisian women with breast cancer[J]. Int J Biol Markers 2008; 23:238-43.
  27. Theodoropoulos PA, Polioudaki H, Agelaki S, et al. Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer[J]. Cancer Lett 2010; 288:99-06. 9.06.027">CrossRef
  28. Abraham BK, Fritz P, McClellan M, et al. Prevalence of CD44+/CD24? low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis[J]. Clin Cancer Res 2005; 11:1154-159.
  29. Aktas B, Tewes M, Fehm T, et al. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients[J]. Breast Cancer Res 2009; 11:R46. CrossRef
  30. Lu J, Fan T, Zhao Q, et al. Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients[J]. Int J Cancer 2010; 126:669-83. CrossRef
  
• 作者单位：Jian-ping Cheng (1)
  Ying Yan (1)
  Xiang-yi Wang (1)
  Yuan-li Lu (1)
  Yan-hua Yuan (1)
  Xiao-li Wang (1)
  Jun Jia (1)
  Jun Ren (1)
  
  1. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education); Department of Medical Oncology, Peking University School of Oncology, Beijing Cancer Hospital & Institute, Beijing, 100142, China
  

文摘

Objective The purpose of this study is to explore RT-PCR method to set up the examination platform for detecting circulating tumor cells (CTC) in peripheral blood from metastatic breast cancer patients. The primary endpoint is to find out the correlation of existence of CTC with clinical responses and progression-free survival (PFS). Methods The breast cancer cell line MCF-7 was serially diluted into the peripheral blood from 45 healthy donors to set up the sensitivity of RT-PCR assay. The expression of CK19 mRNA was amplified from both 49 patients and 45 healthy donors respectively. The CK19 protein quantity from plasma was measured by competitive inhibition ELISA assay. Results The sensitivity of RT-PCR could reach 1/106-07 white blood cells with specificity of 95.6%. The objective response rate (ORR) of patients with CK19 mRNA-negative undertaken one cycle chemotherapy was significantly higher than those with positive (P<0.0001). PFS among CK19 mRNA-negative patients was also increased, although there was no significance (P=0.098). The results of ELISA assay showed that CK19 protein was decreased significantly after one cycle chemotherapy, which gave rise to a little higher ORR (P=0.015) and increased PFS (P=0.016). Conclusion Patients with unamplified CK19 mRNA after one cycle chemotherapy could achieve better radiographic evaluation and increased PFS, which was showed to be of consistency with the CK19 protein assay among the patients treated.